Working...
ClinicalTrials.gov
ClinicalTrials.gov Menu
Trial record 6 of 59 for:    MLN8237

Study to Assess Safety and Tolerability of MLN8237, In Combination With Erlotinib to Treat Non-Small Cell Lung Cancer

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
ClinicalTrials.gov Identifier: NCT01471964
Recruitment Status : Terminated (Phase I portion completed. Phase II will open pending amendment approval.)
First Posted : November 16, 2011
Last Update Posted : May 17, 2018
Sponsor:
Collaborator:
Millennium Pharmaceuticals, Inc.
Information provided by (Responsible Party):
Fox Chase Cancer Center

Brief Summary:
This phase I/II trial studies the side effects and the best dose of MLN8237 when given together with erlotinib hydrochloride and to see how well it works in treating patients with recurrent locally advanced or metastatic non-small cell lung cancer (NSCLC). MLN8237 and erlotinib may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth.

Condition or disease Intervention/treatment Phase
Non-small Cell Lung Cancer Metastatic Non-small Cell Lung Cancer Recurrent Drug: MLN8237 and Erlotinib Phase 1 Phase 2

Detailed Description:

PRIMARY OBJECTIVES:

I. Safety and tolerability of the combination treatment. (Phase I) II. Maximum tolerated dose (MTD) of MLN8237 (alisertib) when given in combination with standard dose erlotinib (erlotinib hydrochloride). (Phase I) III. Progression free survival. (Phase II)

SECONDARY OBJECTIVES:

I. Pharmacokinetic (PK) parameters of erlotinib and MLN8237, including, but not limited to maximum concentration of drug (Cmax), time of occurrence for maximum drug concentration (Tmax), and area under the curve from time zero to the last measurable concentration(AUC0-t last).

II. Overall response rate (ORR), duration of response (DOR), time to progression (TTP), and overall survival (OS). (Phase II) III. Adverse events (AEs), serious adverse events (SAEs), assessments of clinical laboratory values. (Phase II)

OUTLINE: This is a phase I, dose-escalation study of alisertib followed by a phase II study.

Patients receive alisertib orally (PO) twice daily (BID) on days 1-7 and erlotinib hydrochloride PO once daily (QD) on days 1-21. Courses repeat every 21 days for up to 2 years in the absence of disease progression or unacceptable toxicity.

After completion of study treatment, patients are followed up every 3 months for 2 years, every 6 months for 2 years, and then annually thereafter.


Layout table for study information
Study Type : Interventional  (Clinical Trial)
Actual Enrollment : 22 participants
Intervention Model: Single Group Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Official Title: A Phase I/II Trial to Assess Safety and Tolerability of an Oral Aurora Kinase A Inhibitor, MLN8237, In Combination With Erlotinib In Patients With Recurrent or Metastatic Non-Small Cell Lung Cancer
Actual Study Start Date : October 20, 2011
Actual Primary Completion Date : February 7, 2017
Actual Study Completion Date : April 10, 2018

Resource links provided by the National Library of Medicine

MedlinePlus related topics: Lung Cancer

Arm Intervention/treatment
Experimental: MLN8237 and Erlotinib

Phase I Erlotinib 100 mg PO daily* + MLN8237 30 mg PO BID (days 1 - 7), escalating to Erlotinib 150mg PO daily + MLN8237 starting at 30mg PO BID days 1-7, escalating to 40mg BID (days 1 - 7) , then 50mg BID (days 1 - 7).

Phase II Erlotinib 150mg PO daily + MLN8237 at MTD from phase I.

Drug: MLN8237 and Erlotinib
Erlotinib pills once every day and MLN8237 pills twice every day, day 1-7 of every 21 days
Other Names:
  • MLN8237 Aurora A kinase inhibitor, alisertib
  • Erlotinib, CP-358,774, erlotinib hydrochloride
  • Tarceva, OSI-774




Primary Outcome Measures :
  1. Safety and tolerability of the combination treatment (Phase I) [ Time Frame: Participants will be followed for the duration of treatment (up to 2 years) through 30 days of completion of treatment ]
    Toxicity will be evaluated according to the NCI CTCAE, version 4.0.

  2. MTD of alisertib when given in combination with standard dose erlotinib hydrochloride (Phase I) [ Time Frame: Participants will be followed for the duration of treatment (up to 2 years) ]
    MTD is the highest dose tried for which there were either 0 or at most 1 dose-limiting toxicity (DLT) in 6 patients. Any dose that leads to 2 DLTs will be considered too toxic and no additional patients will be treated at that level. Although DLTs may occur at any point during treatment, only DLTs occurring during course 1 of treatment during the Phase 1 portion of this study will necessarily influence decisions regarding dose escalation, expansion of a dose level, or evaluation of intermediate dose levels.

  3. PFS (Phase II) [ Time Frame: Participants will be followed for the duration of treatment (up to 2 years) until the date of first documented progression or date of death for any cause, whichever came first ]
    PFS and OS will be treated by the method of Kaplan and Meier. The Phase II component will follow a two stage design that allows for early termination of the study if the primary end point of PFS is not met. The phase II part will use an early stopping design 36 that evaluates patients at 9 weeks and again at 18 weeks. Patients still progression free at 9 weeks will remain on study until progression or the end of their follow up period.


Secondary Outcome Measures :
  1. PK parameters of erlotinib hydrochloride and alisertib, including, but not limited to Cmax, Tmax, and AUC 0-tlast [ Time Frame: Day 7 and day 21 (optional) of course 1 ]
  2. ORR (Phase II) [ Time Frame: Participants will be followed for the duration of treatment (up to 2 years) until the date of first documented progression or date of death for any cause, whichever came first ]
    RECIST v1.1 criteria will be used for objective tumor response assessment. Assessments will be performed after every three cycles of treatments (every 9 weeks). Once protocol treatment has been completed subjects will be assessed every three months or sooner as indicated and judged by treating physicians.

  3. DOR (Phase II) [ Time Frame: Participants will be followed for the duration of treatment (up to 2 years) until the date of first documented progression or date of death for any cause, whichever came first ]
    The duration of overall response is measured from the time measurement criteria are met for complete response (CR) or partial response (PR) (whichever is first recorded) until the first date that recurrent or progressive disease is objectively documented (taking as reference for progressive disease the smallest measurements recorded since the treatment started).

  4. TTP (Phase II) [ Time Frame: Participants will be followed for the duration of treatment (up to 2 years) until the date of first documented progression or date of death for any cause, whichever came first ]
  5. OS (Phase II) [ Time Frame: Participants will be followed for the duration of treatment (up to 2 years) until the date of first documented progression or date of death for any cause, whichever came first ]
    PFS and OS will be treated by the method of Kaplan and Meier.

  6. AEs, SAEs, and assessments of clinical laboratory values (Phase II) [ Time Frame: Participants will be followed for the duration of treatment (up to 2 years) through 30 days of completion of treatment ]
    AE is any unfavorable and unintended sign (including an abnormal laboratory finding), symptom or disease temporally associated with the use of a medical treatment or procedure regardless of whether it is considered related to the medical treatment or procedure. Attributable AE, with CTCAE v4 grading should be monitored and recorded until resolved to =< grade I or determined to be irreversible.



Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Layout table for eligibility information
Ages Eligible for Study:   18 Years and older   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  • Patients with cytologically or histologically confirmed recurrent locally advanced or metastatic NSCLC have received at least one prior recognized systemic therapy for therapy for advanced disease, (recognized therapy must include a platinum doublet unless contraindicated due to organ dysfunction)
  • Eastern Cooperative Oncology Group (ECOG) Performance Status 0-1
  • Measurable disease by Response Evaluation Criteria in Solid Tumors- (RECIST) 1.1 criteria; previous irradiated tumor is acceptable if there is at least a 20% increase in the size of the previously irradiated lesion
  • Absolute neutrophil count (ANC) >= 1500/mm^3
  • Platelets >= 100,000/mm^3
  • Hemoglobin (Hgb) >= 9g/dL
  • Total bilirubin =< upper limit of normal (ULN)
  • Serum glutamic oxaloacetic transaminase (SGOT) (aspartate aminotransferase [AST]) and serum glutamic pyruvate transaminase (SGPT) (alanine aminotransferase [ALT]) =< 1.5 x ULN; AST and/or ALT may be up to 5 X ULN if with known liver mets
  • Adequate renal function as defined by: calculated creatinine clearance must be at least 40 mL/minute (Cockcroft-Gault)
  • Serious, active infections must be controlled; patients may be enrolled while still on antibiotics as long as clinical signs of active infection are absent
  • Previous radiation allowed provided the patient has recovered from the acute and chronic side effects to =< grade 1 (National Cancer Institute [NCI] Common Terminology Criteria for Adverse Events v. 4.0 [CTCAE v 4.0])
  • Availability of archival diagnostic tissue (paraffin tissue block of resected tumor, core biopsy, fine needle aspirate cell block, or if block cannot be submitted 20-25 [5 micron] unstained slides cut from a block representative of tumor, is required)
  • Able and willing to sign an informed consent and Health Insurance Portability and Accountability Act (HIPAA) authorization
  • Able and willing to swallow and absorb orally administered medications and maintain a fast as required before and after MLN8237 administration
  • Women of childbearing potential (WOCBP) and men who are sexually active, even if surgically sterilized, with WOCBP must agree to use effective methods of contraception during active treatment, for the duration of the study, and for 3 months after the completion of the study

Exclusion Criteria

  • Prior treatment with an investigational or marketed inhibitor of the epidermal growth factor receptor (EGFR) pathway or an Aurora Kinase inhibitor
  • Patients with mutations in the EGFR gene; the mutational status of all patients will be determined prior to study entry
  • Prior malignancy within the past 3 years other than complete resection of basal or squamous cell carcinoma of the skin, any in situ malignancy, or low-risk prostate cancer after curative therapy
  • Prior systemic therapy within 14 days of initiating protocol treatment
  • Radiation therapy to more than 25% of the bone marrow; whole pelvic radiation is considered to be over 25%; (ongoing small field radiation therapy for palliation only is allowed)
  • Treatment with clinically significant enzyme inducers, such as the enzyme-inducing antiepileptic drugs phenytoin, carbamazepine or phenobarbital, or rifampin, rifabutin, rifapentine or St. John's wort within 14 days prior to the first dose of MLN8237 and during the study; anticonvulsants at stable doses are allowed
  • Treatment with Proton Pump Inhibitor (PPI); patients on PPI therapy prior to enrollment must stop using the PPI for at least 4 days prior to the first dose of MLN8237
  • Known central nervous system (CNS) disease, except for treated brain metastasis; treated brain metastases are defined as having no evidence of progression or hemorrhage after treatment and no ongoing requirement for dexamethasone, as ascertained by clinical examination and brain imaging (magnetic resonance imaging [MRI] or computed tomography [CT]) during the screening period; anticonvulsants (stable doses) are allowed; treatment for brain metastases may include whole brain radiotherapy (WBRT), radiosurgery (RS; Gamma Knife, linear accelerator [LINAC], or equivalent) or a combination as deemed appropriate by the treating physician; patients with CNS metastases treated by neurosurgical resection or brain biopsy performed < 4 weeks prior to Day 1 will be excluded
  • Uncontrolled or unstable medical or psychiatric co-morbidities which would clearly preclude use of MLN8237 or erlotinib
  • Current, recent (within 2 weeks of enrollment of this study), or planned participation in an experimental drug study
  • Unstable angina
  • New York Heart Association (NYHA) Grade III or greater congestive heart failure
  • History of myocardial infarction within 6 months of enrollment
  • Abnormal electrocardiogram (EKG): severe uncontrolled ventricular arrhythmias, or evidence of acute ischemia or active conduction system abnormalities; prior to study entry, any EKG abnormality at screening has to be documented by the investigator as not medically relevant
  • Pregnant (positive serum pregnancy test) or breast feeding
  • History of any disease that could lead to impaired absorption of drugs
  • Known hypersensitivity to any component of the trial agents
  • Inability to comply with study and/or follow-up procedures
  • Prior allogeneic bone marrow or organ transplantation
  • Patient has >= grade 2 (CTCAE v 4.0) peripheral neuropathy within 14 days before enrollment
  • Known history of uncontrolled sleep apnea syndrome and other conditions according to enrolling investigator that could result in excessive daytime sleepiness, such as severe chronic obstructive pulmonary disease; requirement for supplemental oxygen therapy; or requirement of recurrent thoracentesis to manage pleural effusions
  • Known history of human immunodeficiency virus (HIV) infection, hepatitis B, or hepatitis C; testing is not required in the absence of clinical findings or suspicion

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT01471964


Locations
Layout table for location information
United States, Pennsylvania
Fox Chase Cancer Center
Philadelphia, Pennsylvania, United States, 19111
Sponsors and Collaborators
Fox Chase Cancer Center
Millennium Pharmaceuticals, Inc.
Investigators
Layout table for investigator information
Principal Investigator: Hossein Borghaei, DO Fox Chase Cancer Center

Layout table for additonal information
Responsible Party: Fox Chase Cancer Center
ClinicalTrials.gov Identifier: NCT01471964     History of Changes
Other Study ID Numbers: OER-TH-036
NCI-2011-03306 ( Other Identifier: NCI CTRP Registration Site )
First Posted: November 16, 2011    Key Record Dates
Last Update Posted: May 17, 2018
Last Verified: May 2018

Additional relevant MeSH terms:
Layout table for MeSH terms
Lung Neoplasms
Carcinoma, Non-Small-Cell Lung
Respiratory Tract Neoplasms
Thoracic Neoplasms
Neoplasms by Site
Neoplasms
Lung Diseases
Respiratory Tract Diseases
Carcinoma, Bronchogenic
Bronchial Neoplasms
Erlotinib Hydrochloride
Antineoplastic Agents
Protein Kinase Inhibitors
Enzyme Inhibitors
Molecular Mechanisms of Pharmacological Action